Athira Pharma (LONA) Competitors

$9.63 +0.08 (+0.84%)

Closing price 03:59 PM Eastern

Extended Trading

$9.60 -0.04 (-0.36%)

As of 04:10 PM Eastern

LONA vs. EOLS, AVXL, EDIT, SIGA, and NERV

Should you be buying Athira Pharma stock or one of its competitors? The main competitors of Athira Pharma include Evolus (EOLS), Anavex Life Sciences (AVXL), Editas Medicine (EDIT), Siga Technologies (SIGA), and Minerva Neurosciences (NERV). These companies are all part of the "pharmaceutical products" industry.

How does Athira Pharma compare to Evolus?

Evolus (NASDAQ:EOLS) and Athira Pharma (NASDAQ:LONA) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.

: Athira Pharma has a net margin of 0.00% compared to Evolus' net margin of -17.38%. Evolus' return on equity of 0.00% beat Athira Pharma's return on equity.
Company Net Margins Return on Equity Return on Assets
Evolus -17.38% N/A -21.57%
Athira Pharma N/A -340.97% -209.91%
: In the previous week, Evolus had 10 more articles in the media than Athira Pharma. MarketBeat recorded 11 mentions for Evolus and 1 mentions for Athira Pharma. Evolus' average media sentiment score of -0.11 beat Athira Pharma's score of -1.74 indicating that Evolus is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Evolus
2 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Athira Pharma
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Very Negative
: 90.7% of Evolus shares are owned by institutional investors. Comparatively, 57.1% of Athira Pharma shares are owned by institutional investors. 5.9% of Evolus shares are owned by company insiders. Comparatively, 25.1% of Athira Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
: Evolus has higher revenue and earnings than Athira Pharma. Evolus is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Evolus $297.18M 1.39 -$51.64M -$0.81 N/A
Athira Pharma N/A N/A -$105.61M -$9.68 N/A
: Evolus currently has a consensus target price of $16.00, suggesting a potential upside of 151.57%. Athira Pharma has a consensus target price of $10.00, suggesting a potential upside of 3.84%. Given Evolus' stronger consensus rating and higher probable upside, analysts plainly believe Evolus is more favorable than Athira Pharma.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Evolus
1 Sell rating(s)
1 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.50
Athira Pharma
1 Sell rating(s)

1 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.25
: Evolus has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500. Comparatively, Athira Pharma has a beta of 1.98, meaning that its stock price is 98% more volatile than the S&P 500.

Company	Net Margins	Return on Equity	Return on Assets
Evolus	-17.38%	N/A	-21.57%
Athira Pharma	N/A	-340.97%	-209.91%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evolus	2 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Athira Pharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Very Negative

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evolus	$297.18M	1.39	-$51.64M	-$0.81	N/A
Athira Pharma	N/A	N/A	-$105.61M	-$9.68	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evolus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Evolus beats Athira Pharma on 11 of the 15 factors compared between the two stocks.

How does Athira Pharma compare to Anavex Life Sciences?

Athira Pharma (NASDAQ:LONA) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations, media sentiment and institutional ownership.

: Anavex Life Sciences' return on equity of -38.76% beat Athira Pharma's return on equity.
Company Net Margins Return on Equity Return on Assets
Athira Pharma N/A -340.97% -209.91%
Anavex Life Sciences N/A -38.76% -35.01%
: In the previous week, Anavex Life Sciences had 5 more articles in the media than Athira Pharma. MarketBeat recorded 6 mentions for Anavex Life Sciences and 1 mentions for Athira Pharma. Anavex Life Sciences' average media sentiment score of 0.90 beat Athira Pharma's score of -1.74 indicating that Anavex Life Sciences is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Athira Pharma
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Very Negative
Anavex Life Sciences
1 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: 57.1% of Athira Pharma shares are held by institutional investors. Comparatively, 31.5% of Anavex Life Sciences shares are held by institutional investors. 25.1% of Athira Pharma shares are held by insiders. Comparatively, 11.4% of Anavex Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
: Anavex Life Sciences is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Athira Pharma N/A N/A -$105.61M -$9.68 N/A
Anavex Life Sciences N/A N/A -$46.38M -$0.46 N/A
: Athira Pharma currently has a consensus target price of $10.00, suggesting a potential upside of 3.84%. Anavex Life Sciences has a consensus target price of $21.33, suggesting a potential upside of 534.92%. Given Anavex Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Anavex Life Sciences is more favorable than Athira Pharma.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Athira Pharma
1 Sell rating(s)
1 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.25
Anavex Life Sciences
1 Sell rating(s)

1 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.40
: Athira Pharma has a beta of 1.98, suggesting that its share price is 98% more volatile than the S&P 500. Comparatively, Anavex Life Sciences has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-340.97%	-209.91%
Anavex Life Sciences	N/A	-38.76%	-35.01%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Athira Pharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Very Negative
Anavex Life Sciences	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$105.61M	-$9.68	N/A
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.46	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Anavex Life Sciences beats Athira Pharma on 9 of the 13 factors compared between the two stocks.

How does Athira Pharma compare to Editas Medicine?

Editas Medicine (NASDAQ:EDIT) and Athira Pharma (NASDAQ:LONA) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.

: Editas Medicine presently has a consensus target price of $5.40, suggesting a potential upside of 78.81%. Athira Pharma has a consensus target price of $10.00, suggesting a potential upside of 3.84%. Given Editas Medicine's stronger consensus rating and higher possible upside, analysts plainly believe Editas Medicine is more favorable than Athira Pharma.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Editas Medicine
1 Sell rating(s)
1 Hold rating(s)

5 Buy rating(s)

0 Strong Buy rating(s)
2.57
Athira Pharma
1 Sell rating(s)

1 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.25
: Athira Pharma has a net margin of 0.00% compared to Editas Medicine's net margin of -395.02%. Athira Pharma's return on equity of -340.97% beat Editas Medicine's return on equity.
Company Net Margins Return on Equity Return on Assets
Editas Medicine -395.02% -389.73% -55.28%
Athira Pharma N/A -340.97% -209.91%
: In the previous week, Editas Medicine had 9 more articles in the media than Athira Pharma. MarketBeat recorded 10 mentions for Editas Medicine and 1 mentions for Athira Pharma. Editas Medicine's average media sentiment score of 0.61 beat Athira Pharma's score of -1.74 indicating that Editas Medicine is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Editas Medicine
3 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Positive
Athira Pharma
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Very Negative
: Athira Pharma has lower revenue, but higher earnings than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Editas Medicine $40.52M 7.30 -$160.06M -$1.89 N/A
Athira Pharma N/A N/A -$105.61M -$9.68 N/A
: 71.9% of Editas Medicine shares are held by institutional investors. Comparatively, 57.1% of Athira Pharma shares are held by institutional investors. 2.1% of Editas Medicine shares are held by company insiders. Comparatively, 25.1% of Athira Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
: Editas Medicine has a beta of 2.14, meaning that its stock price is 114% more volatile than the S&P 500. Comparatively, Athira Pharma has a beta of 1.98, meaning that its stock price is 98% more volatile than the S&P 500.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Company	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-395.02%	-389.73%	-55.28%
Athira Pharma	N/A	-340.97%	-209.91%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Editas Medicine	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Athira Pharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Very Negative

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$40.52M	7.30	-$160.06M	-$1.89	N/A
Athira Pharma	N/A	N/A	-$105.61M	-$9.68	N/A

Summary

Editas Medicine beats Athira Pharma on 10 of the 15 factors compared between the two stocks.

How does Athira Pharma compare to Siga Technologies?

Siga Technologies (NASDAQ:SIGA) and Athira Pharma (NASDAQ:LONA) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.

: 55.4% of Siga Technologies shares are held by institutional investors. Comparatively, 57.1% of Athira Pharma shares are held by institutional investors. 2.0% of Siga Technologies shares are held by company insiders. Comparatively, 25.1% of Athira Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
: Athira Pharma has a consensus target price of $10.00, suggesting a potential upside of 3.84%. Given Athira Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Athira Pharma is more favorable than Siga Technologies.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Siga Technologies
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
Athira Pharma
1 Sell rating(s)

1 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.25
: Siga Technologies has a net margin of 24.61% compared to Athira Pharma's net margin of 0.00%. Siga Technologies' return on equity of 11.25% beat Athira Pharma's return on equity.
Company Net Margins Return on Equity Return on Assets
Siga Technologies 24.61% 11.25% 9.98%
Athira Pharma N/A -340.97% -209.91%
: In the previous week, Siga Technologies had 2 more articles in the media than Athira Pharma. MarketBeat recorded 3 mentions for Siga Technologies and 1 mentions for Athira Pharma. Siga Technologies' average media sentiment score of 0.67 beat Athira Pharma's score of -1.74 indicating that Siga Technologies is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Siga Technologies
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Athira Pharma
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Very Negative
: Siga Technologies has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500. Comparatively, Athira Pharma has a beta of 1.98, meaning that its stock price is 98% more volatile than the S&P 500.
: Siga Technologies has higher revenue and earnings than Athira Pharma. Athira Pharma is trading at a lower price-to-earnings ratio than Siga Technologies, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Siga Technologies $94.57M 3.52 $23.28M $0.31 14.97
Athira Pharma N/A N/A -$105.61M -$9.68 N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Siga Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Company	Net Margins	Return on Equity	Return on Assets
Siga Technologies	24.61%	11.25%	9.98%
Athira Pharma	N/A	-340.97%	-209.91%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Siga Technologies	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Athira Pharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Very Negative

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Siga Technologies	$94.57M	3.52	$23.28M	$0.31	14.97
Athira Pharma	N/A	N/A	-$105.61M	-$9.68	N/A

Summary

Siga Technologies beats Athira Pharma on 9 of the 15 factors compared between the two stocks.

How does Athira Pharma compare to Minerva Neurosciences?

Minerva Neurosciences (NASDAQ:NERV) and Athira Pharma (NASDAQ:LONA) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

: 34.6% of Minerva Neurosciences shares are held by institutional investors. Comparatively, 57.1% of Athira Pharma shares are held by institutional investors. 10.4% of Minerva Neurosciences shares are held by company insiders. Comparatively, 25.1% of Athira Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
: Minerva Neurosciences presently has a consensus target price of $10.50, suggesting a potential upside of 68.00%. Athira Pharma has a consensus target price of $10.00, suggesting a potential upside of 3.84%. Given Minerva Neurosciences' higher probable upside, equities analysts clearly believe Minerva Neurosciences is more favorable than Athira Pharma.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Minerva Neurosciences
1 Sell rating(s)
1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
Athira Pharma
1 Sell rating(s)

1 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.25
: Minerva Neurosciences' return on equity of 0.00% beat Athira Pharma's return on equity.
Company Net Margins Return on Equity Return on Assets
Minerva Neurosciences N/A N/A -35.62%
Athira Pharma N/A -340.97% -209.91%
: In the previous week, Minerva Neurosciences had 3 more articles in the media than Athira Pharma. MarketBeat recorded 4 mentions for Minerva Neurosciences and 1 mentions for Athira Pharma. Minerva Neurosciences' average media sentiment score of 1.25 beat Athira Pharma's score of -1.74 indicating that Minerva Neurosciences is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Minerva Neurosciences
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Athira Pharma
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Very Negative
: Minerva Neurosciences has a beta of -0.08, meaning that its share price is 108% less volatile than the S&P 500. Comparatively, Athira Pharma has a beta of 1.98, meaning that its share price is 98% more volatile than the S&P 500.
: Athira Pharma is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Minerva Neurosciences N/A N/A -$293.42M -$26.80 N/A
Athira Pharma N/A N/A -$105.61M -$9.68 N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Minerva Neurosciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Company	Net Margins	Return on Equity	Return on Assets
Minerva Neurosciences	N/A	N/A	-35.62%
Athira Pharma	N/A	-340.97%	-209.91%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Minerva Neurosciences	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Athira Pharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Very Negative

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Minerva Neurosciences	N/A	N/A	-$293.42M	-$26.80	N/A
Athira Pharma	N/A	N/A	-$105.61M	-$9.68	N/A

Summary

Athira Pharma beats Minerva Neurosciences on 7 of the 13 factors compared between the two stocks.

Get Athira Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LONA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LONA vs. The Competition

Export

Metric	Athira Pharma	Biological Products, Except Diagnostic Substances Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$90.43M	$362.87M	$4.21B	$11.87B
Dividend Yield	N/A	N/A	5.61%	5.21%
P/E Ratio	-0.99	N/A	23.40	28.47
Price / Sales	N/A	372.54	186.69	60.92
Price / Cash	N/A	N/A	52.82	36.52
Price / Book	3.23	2.81	38.31	6.67
Net Income	-$105.61M	-$81.71M	$114.66M	$332.53M
7 Day Performance	10.82%	6.50%	1.23%	2.01%
1 Month Performance	-15.15%	5.53%	5.54%	9.19%
1 Year Performance	N/A	N/A	18.68%	39.59%

Athira Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LONA Athira Pharma	0.8162 of 5 stars	$9.63 +0.8%	$10.00 +3.8%	N/A	$90.43M	N/A	N/A	40
EOLS Evolus	2.0713 of 5 stars	$5.31 +2.3%	$16.00 +201.3%	N/A	$337.66M	$297.18M	N/A	170	Trending News Earnings Report Gap Down
AVXL Anavex Life Sciences	2.3108 of 5 stars	$3.31 -8.3%	$22.00 +564.7%	N/A	$334.55M	N/A	N/A	40	News Coverage Positive News Upcoming Earnings Analyst Forecast
EDIT Editas Medicine	3.3517 of 5 stars	$3.21 -3.6%	$5.30 +65.1%	N/A	$325.91M	$40.52M	N/A	230	News Coverage Earnings Report Analyst Upgrade
SIGA Siga Technologies	1.4019 of 5 stars	$4.53 +0.4%	N/A	N/A	$323.12M	$94.57M	14.61	40	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LONA) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Athira Pharma (LONA) Competitors

LONA vs. EOLS, AVXL, EDIT, SIGA, and NERV

How does Athira Pharma compare to Evolus?

Summary

How does Athira Pharma compare to Anavex Life Sciences?

Summary

How does Athira Pharma compare to Editas Medicine?

Summary

How does Athira Pharma compare to Siga Technologies?

Summary

How does Athira Pharma compare to Minerva Neurosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LONA vs. The Competition

Athira Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Athira Pharma (LONA) Competitors

LONA vs. EOLS, AVXL, EDIT, SIGA, and NERV

How does Athira Pharma compare to Evolus?

Summary

How does Athira Pharma compare to Anavex Life Sciences?

Summary

How does Athira Pharma compare to Editas Medicine?

Summary

How does Athira Pharma compare to Siga Technologies?

Summary

How does Athira Pharma compare to Minerva Neurosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LONA vs. The Competition

Athira Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools